|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00488371 |
|
Date of registration:
|
18/06/2007 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®
|
|
Scientific title:
|
Evaluation of Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Pneumococcal Conjugated Vaccine (Prevnar®) Under the Auspices of the Taipei City Government Vaccination Program |
|
Date of first enrolment:
|
November 2006 |
|
Target sample size:
|
250 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00488371 |
|
Study type:
|
Observational |
|
Study design:
|
Time Perspective: Prospective
|
|
Phase:
|
|
|
|
Contacts
|
|
Name:
|
Trial Manager |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
For Taiwan, medinfo@wyeth.com |
|
|
Name:
|
Medical Monitor |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Wyeth is now a wholly owned subsidiary of Pfizer |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria
- Healthy children aged 2 to 5 years old identified by the Taipei City government and
are participating in Taipei City's PCV7 vaccination program.
- Informed consent obtained from parents or legal guardian.
- Eligible to receive 1 dose of PCV7
Exclusion criteria
- Children with any of the following conditions: immunologic diseases; neoplastic
disorders; renal, cardiac, hepatic, or hematologic diseases; bronchodysplasia; Down
syndrome; chronic otitis media with effusion.
- Children with any acute illness including mild acute respiratory infection or fever >
38 centigrade.
Age minimum:
2 Years
Age maximum:
5 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Pneumococcal Infections
|
|
Intervention(s)
|
|
Biological: Pneumococcal Conjugated Vaccine (Prevnar®)
|
|
Secondary ID(s)
|
|
0887X1-4410
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|